StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
78
This year
4
Publishing Date
2023 - 11 - 02
2
2023 - 10 - 25
2
2023 - 09 - 13
2
2023 - 08 - 03
1
2023 - 07 - 24
1
2023 - 07 - 19
1
2023 - 07 - 17
1
2023 - 06 - 30
1
2023 - 05 - 04
1
2023 - 04 - 26
2
2023 - 04 - 24
1
2023 - 03 - 08
1
2023 - 02 - 23
1
2023 - 02 - 21
2
2023 - 01 - 16
1
2022 - 12 - 21
1
2022 - 12 - 15
1
2022 - 12 - 08
1
2022 - 11 - 21
1
2022 - 11 - 03
1
2022 - 11 - 01
1
2022 - 09 - 20
1
2022 - 09 - 15
2
2022 - 09 - 13
2
2022 - 09 - 12
1
2022 - 09 - 08
1
2022 - 08 - 29
1
2022 - 08 - 24
1
2022 - 08 - 18
1
2022 - 08 - 03
1
2022 - 07 - 28
1
2022 - 07 - 27
2
2022 - 06 - 14
1
2022 - 06 - 09
1
2022 - 06 - 02
1
2022 - 05 - 24
1
2022 - 03 - 01
1
2022 - 02 - 10
1
2022 - 01 - 19
1
2021 - 12 - 22
1
2021 - 12 - 20
1
2021 - 12 - 14
1
2021 - 12 - 12
1
2021 - 11 - 05
1
2021 - 10 - 28
1
2021 - 08 - 03
1
2021 - 07 - 01
1
2021 - 05 - 28
1
2021 - 05 - 21
1
2021 - 05 - 20
1
2021 - 05 - 05
1
2021 - 05 - 03
1
2021 - 04 - 29
1
2021 - 04 - 23
1
2021 - 04 - 22
1
2021 - 04 - 16
1
2021 - 04 - 14
1
2021 - 04 - 13
1
2021 - 04 - 09
1
2021 - 04 - 07
1
Sector
Commercial services
1
Consumer non-durables
1
Health technology
78
Manufacturing
3
Professional, scientific, and technical services
2
Tags
Active
1
Alliances
1
Als
1
Alzheimer
1
Alzheimer's
1
Alzheimer's disease
1
Alzheimer’s
5
Application
9
Approval
12
Blood
2
Cancer
10
Cardiovascular
2
Clinical-trials-phase-i
6
Clinical-trials-phase-iii
6
Companies
2
Day
2
Disease
8
Drug
6
Earnings
7
Europe
2
Events
2
Fda
6
Financial
8
Financial results
4
Food
4
Genetic
2
Genetown
19
Global
2
Growth
2
Hypertension
2
Liver
2
Market
5
Meeting
3
N/a
24
Nash
2
Nephropathy
2
Obesity
2
Offering
2
Ongoing
2
Onpattro
3
Oxlumo
2
Pharmaceutical
2
Pharmaceuticals
4
Phase 1
2
Phase 2
2
Phase 3
4
Pipeline
2
Positive
13
Publication
3
Report
7
Research
6
Results
26
Review
2
Risk
2
Study
11
Technology
2
Therapeutics
3
Topline
4
Treatment
17
Year
3
Entities
89bio, inc.
2
Abbott laboratories
2
Abbvie inc.
12
Abeona therapeutics inc.
2
Acadia pharmaceuticals inc.
4
Adaptimmune therapeutics plc
3
Adc therapeutics sa
5
Agios pharmaceuticals, inc.
12
Alkermes plc
4
Alnylam pharmaceuticals, inc.
243
Altimmune, inc.
2
Amgen inc.
11
Applied genetic technologies corporation
2
Arrowhead pharmaceuticals, inc.
2
Astellas pharma inc
2
Aveo pharmaceuticals, inc.
10
Axcella health inc.
2
Beigene, ltd.
10
Biogen inc.
5
Biontech se
2
Bluebird bio, inc.
3
Blueprint medicines corporation
14
Bristol-myers squibb company
11
Clovis oncology, inc.
10
Crispr therapeutics ag
2
Danaher corporation
3
Editas medicine, inc.
4
Eli lilly and company
38
Epizyme, inc.
11
Exelixis, inc.
14
Gilead sciences, inc.
6
Illumina, inc.
10
Incyte corporation
14
Intellia therapeutics, inc.
4
Ionis pharmaceuticals, inc.
11
Ironwood pharmaceuticals, inc.
4
Jazz pharmaceuticals plc
4
Johnson & johnson
8
Karyopharm therapeutics inc.
10
Madrigal pharmaceuticals, inc.
3
Moderna, inc.
6
Neurocrine biosciences, inc.
4
Novartis ag
5
Novo nordisk a/s
25
Pfizer, inc.
14
Ptc therapeutics, inc.
4
Regeneron pharmaceuticals, inc.
24
Rigel pharmaceuticals, inc.
10
Royalty pharma plc
3
Sage therapeutics, inc.
4
Sangamo therapeutics, inc.
4
Sanofi
78
Sarepta therapeutics, inc.
8
Teva pharmaceutical industries ltd
4
Ultragenyx pharmaceutical inc.
5
United therapeutics corporation
4
Verastem, inc.
10
Vir biotechnology, inc.
24
Xencor, inc.
4
Y-mabs therapeutics, inc.
10
Symbols
ABBV
211
ABT
253
ALNY
78
ALPMF
70
ALPMY
70
AMGN
170
AMRN
36
AZN
214
AZNCF
174
BAX
45
BDX
34
BHC
30
BIIB
53
BMRN
29
BMY
119
BNTX
167
BSX
25
BY
26
CMXHF
22
FNCTF
49
GILD
64
GLAXF
271
GLPG
41
GLPGF
41
GOOG
37
GOOGL
37
GSK
335
IGMS
37
INCY
121
IPHA
109
IPHYF
81
JNJ
578
KPTI
25
KYMR
29
LLY
335
MDT
45
MOBV
65
MOR
41
MPSYF
38
MRNA
34
NKTR
48
NVO
139
NVS
330
NVSEF
285
OCX
37
PFE
153
PRGO
112
PRVB
283
PTCT
37
RCFA
83
REGN
255
RLYB
36
SNY
4553
SNYNF
3611
TAK
60
TEVJF
224
TMO
43
TXMD
36
VTRS
87
VXRT
38
Exchanges
Nasdaq
78
Nyse
16
Crawled Date
2023 - 11 - 02
2
2023 - 10 - 25
2
2023 - 09 - 13
2
2023 - 08 - 03
1
2023 - 07 - 24
1
2023 - 07 - 19
1
2023 - 07 - 17
1
2023 - 06 - 30
1
2023 - 05 - 04
1
2023 - 04 - 26
2
2023 - 04 - 24
1
2023 - 03 - 08
1
2023 - 02 - 23
1
2023 - 02 - 21
2
2023 - 01 - 16
1
2022 - 12 - 21
1
2022 - 12 - 15
1
2022 - 12 - 08
1
2022 - 11 - 21
1
2022 - 11 - 03
1
2022 - 11 - 01
1
2022 - 09 - 20
1
2022 - 09 - 15
2
2022 - 09 - 13
2
2022 - 09 - 12
1
2022 - 09 - 08
1
2022 - 08 - 29
1
2022 - 08 - 24
1
2022 - 08 - 18
1
2022 - 08 - 03
1
2022 - 07 - 28
1
2022 - 07 - 27
2
2022 - 06 - 14
1
2022 - 06 - 09
1
2022 - 06 - 02
1
2022 - 05 - 24
1
2022 - 03 - 01
1
2022 - 02 - 10
1
2022 - 01 - 19
1
2021 - 12 - 22
1
2021 - 12 - 20
1
2021 - 12 - 14
1
2021 - 12 - 12
1
2021 - 11 - 05
1
2021 - 10 - 28
1
2021 - 08 - 03
1
2021 - 07 - 01
1
2021 - 05 - 28
1
2021 - 05 - 21
1
2021 - 05 - 20
1
2021 - 05 - 05
1
2021 - 05 - 03
1
2021 - 04 - 29
1
2021 - 04 - 23
1
2021 - 04 - 22
1
2021 - 04 - 16
1
2021 - 04 - 14
1
2021 - 04 - 13
1
2021 - 04 - 09
1
2021 - 04 - 07
1
Crawled Time
06:00
1
07:00
1
08:00
1
09:00
1
10:00
1
11:00
3
12:00
9
12:20
2
12:30
2
13:00
13
13:20
1
13:30
1
13:50
1
14:00
5
14:30
4
15:00
3
16:00
7
17:37
1
18:04
1
18:26
1
18:31
2
18:33
1
18:40
1
18:42
1
19:00
1
20:00
1
20:20
1
20:59
1
21:00
2
22:00
5
23:00
3
Source
www.alnylam.com
1
www.biospace.com
54
www.fda.gov
10
www.globenewswire.com
5
www.prnewswire.com
8
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Sanofi
symbols :
ALNY
save search
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published:
2024-03-05
(Crawled : 16:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
0.13%
|
O:
1.17%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-2.65%
|
O:
-0.73%
H:
1.52%
C:
0.5%
positive
blood
care
topline
results
study
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Published:
2024-02-15
(Crawled : 14:30)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
480
|
Health Technology
|
4.2%
|
O:
1.16%
H:
1.48%
C:
0.89%
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
3.07%
|
O:
1.86%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-11.01%
|
O:
-8.62%
H:
2.18%
C:
-1.71%
year
pharmaceuticals
financial
results
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published:
2024-02-12
(Crawled : 20:00)
- prnewswire.com
ALPMY
|
News
|
$9.49
-0.42%
-1.11%
55K
|
Manufacturing
|
-12.29%
|
O:
0.37%
H:
0.74%
C:
0.28%
BMY
|
$48.99
-0.31%
0.41%
7.1M
|
Health Technology
|
-1.53%
|
O:
-0.18%
H:
0.48%
C:
-1.91%
ABBV
|
News
|
$169.54
0.98%
0.18%
3.2M
|
Health Technology
|
-2.04%
|
O:
0.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
1.86%
|
O:
-0.06%
H:
0.0%
C:
0.0%
GILD
|
$67.03
0.12%
0.12%
15K
|
Health Technology
|
-9.97%
|
O:
0.32%
H:
0.11%
C:
-1.55%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-13.74%
|
O:
-2.63%
H:
0.98%
C:
-1.75%
liver
disease
therapeutics
market
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published:
2024-02-02
(Crawled : 12:00)
- globenewswire.com
TSVT
|
$4.63
-0.43%
-0.43%
260K
|
|
-10.79%
|
O:
-1.16%
H:
9.94%
C:
2.34%
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-2.89%
|
O:
-0.93%
H:
0.0%
C:
0.0%
REGN
|
News
|
$907.32
0.8%
0.74%
220K
|
Health Technology
|
-5.27%
|
O:
1.4%
H:
0.28%
C:
-2.68%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-16.49%
|
O:
-1.23%
H:
1.0%
C:
0.17%
year
financial
results
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
Published:
2023-12-13
(Crawled : 14:30)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
480
|
Health Technology
|
0.52%
|
O:
-0.06%
H:
2.36%
C:
2.36%
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-0.74%
|
O:
-0.27%
H:
2.28%
C:
2.16%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-15.99%
|
O:
-0.14%
H:
4.22%
C:
3.97%
day
innovation
pipeline
platform
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
Published:
2023-11-03
(Crawled : 11:00)
- globenewswire.com
SNYNF
|
News
|
$94.25
1.67%
-2.18%
480
|
Health Technology
|
1.89%
|
O:
-1.79%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
0.11%
|
O:
-3.04%
H:
0.0%
C:
0.0%
REGN
|
News
|
$907.32
0.8%
0.74%
220K
|
Health Technology
|
10.81%
|
O:
2.37%
H:
0.12%
C:
-2.54%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-9.57%
|
O:
1.95%
H:
2.7%
C:
1.62%
disorders
pipeline
blood
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
Published:
2023-11-02
(Crawled : 13:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
3.11%
|
O:
3.0%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-6.96%
|
O:
3.4%
H:
0.57%
C:
-0.5%
pharmaceuticals
financial
results
Regeneron Reports Third Quarter 2023 Financial and Operating Results
Published:
2023-11-02
(Crawled : 11:00)
- globenewswire.com
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
3.11%
|
O:
3.0%
H:
0.0%
C:
0.0%
REGN
|
News
|
$907.32
0.8%
0.74%
220K
|
Health Technology
|
14.67%
|
O:
0.08%
H:
4.96%
C:
3.4%
NTLA
|
$21.53
-1.37%
-1.37%
650K
|
Health Technology
|
-15.57%
|
O:
2.35%
H:
1.63%
C:
1.46%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-6.96%
|
O:
3.4%
H:
0.57%
C:
-0.5%
financial
results
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
Published:
2023-10-25
(Crawled : 23:00)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
480
|
Health Technology
|
-8.94%
|
O:
0.4%
H:
1.29%
C:
1.29%
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-10.17%
|
O:
1.43%
H:
0.64%
C:
-0.09%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-10.91%
|
O:
-1.28%
H:
0.58%
C:
-1.46%
publication
results
study
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-10-25
(Crawled : 19:00)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
480
|
Health Technology
|
-8.94%
|
O:
0.4%
H:
1.29%
C:
1.29%
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-10.17%
|
O:
1.43%
H:
0.64%
C:
-0.09%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-10.91%
|
O:
-1.28%
H:
0.58%
C:
-1.46%
disease
alzheimer’s
positive
results
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-10-09
(Crawled : 14:30)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-12.64%
|
O:
0.19%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-17.44%
|
O:
-4.06%
H:
2.17%
C:
-0.83%
fda
drug
treatment
application
response
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-10-06
(Crawled : 13:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-12.8%
|
O:
-0.19%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-18.26%
|
O:
-0.16%
H:
1.44%
C:
-0.84%
RNA Therapeutics Market worth $18.0 billion | MarketsandMarkets
Published:
2023-09-15
(Crawled : 15:00)
- prnewswire.com
SNYNF
|
News
|
$94.25
1.67%
-2.18%
480
|
Health Technology
|
-13.01%
|
O:
1.53%
H:
0.0%
C:
0.0%
NVSEF
|
News
|
$96.0
0.94%
6.88%
0
|
Health Technology
|
13.27%
|
O:
0.79%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.49
-0.42%
-1.11%
55K
|
Manufacturing
|
-36.69%
|
O:
3.0%
H:
0.0%
C:
-3.43%
PFE
|
News
4
|
$26.32
0.23%
0.15%
20M
|
Health Technology
|
-22.93%
|
O:
-0.26%
H:
1.04%
C:
0.03%
NVS
|
News
|
$97.28
2.27%
1.21%
3.5M
|
Health Technology
|
-2.92%
|
O:
1.51%
H:
0.26%
C:
-0.72%
SRPT
|
$117.12
0.14%
0.09%
570K
|
Health Technology
|
-2.17%
|
O:
-0.27%
H:
0.54%
C:
-0.84%
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-13.73%
|
O:
0.82%
H:
0.0%
C:
0.0%
MRNA
|
News
S
|
$107.89
3.28%
3.16%
2M
|
Health Technology
|
-4.36%
|
O:
0.16%
H:
2.0%
C:
1.42%
IONS
|
$41.84
1.88%
1.86%
260
|
Health Technology
|
-4.12%
|
O:
-0.57%
H:
0.35%
C:
-1.11%
BNTX
|
News
|
$88.49
0.55%
0.59%
1K
|
Health Technology
|
-22.25%
|
O:
0.17%
H:
0.48%
C:
-0.82%
ARWR
|
$23.78
-0.59%
-0.61%
830K
|
Health Technology
|
-22.13%
|
O:
0.16%
H:
0.46%
C:
-5.46%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-24.34%
|
O:
-0.74%
H:
2.42%
C:
-3.47%
therapeutics
market
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-09-13
(Crawled : 22:00)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
480
|
Health Technology
|
-13.88%
|
O:
-1.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-14.08%
|
O:
-0.99%
H:
0.0%
C:
0.0%
fda
positive
treatment
meeting
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-09-13
(Crawled : 12:00)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
480
|
Health Technology
|
-13.88%
|
O:
-1.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-14.08%
|
O:
-0.99%
H:
0.0%
C:
0.0%
fda
drug
review
treatment
application
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
Published:
2023-09-07
(Crawled : 14:30)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-10.67%
|
O:
1.03%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-27.49%
|
O:
-0.15%
H:
1.32%
C:
-0.02%
positive
treat
risk
topline
hypertension
cardiovascular
results
study
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
Published:
2023-08-03
(Crawled : 13:00)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
480
|
Health Technology
|
-8.54%
|
O:
-1.6%
H:
0.11%
C:
0.11%
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-9.75%
|
O:
-3.79%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-20.88%
|
O:
-1.35%
H:
5.58%
C:
4.38%
pharmaceuticals
financial
results
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Published:
2023-07-24
(Crawled : 06:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-14.13%
|
O:
-0.88%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-27.72%
|
O:
0.06%
H:
0.0%
C:
0.0%
partnership
treatment
risk
hypertension
roche
cardiovascular
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
Published:
2023-07-19
(Crawled : 22:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-11.96%
|
O:
0.88%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-29.92%
|
O:
0.74%
H:
0.28%
C:
-2.21%
publication
results
study
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-07-17
(Crawled : 09:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.6M
|
Health Technology
|
-10.72%
|
O:
0.02%
H:
0.0%
C:
0.0%
REGN
|
News
|
$907.32
0.8%
0.74%
220K
|
Health Technology
|
26.28%
|
O:
0.05%
H:
1.33%
C:
0.38%
ALNY
|
$146.07
0.19%
0.18%
540K
|
Health Technology
|
-25.89%
|
O:
5.53%
H:
5.23%
C:
-2.49%
disease
alzheimer’s
positive
results
← Previous
1
2
3
4
Next →
Gainers vs Losers
77%
23%
Top 10 Gainers
AGBA
|
$2.97
137.6%
54.87%
66M
|
Finance
HKIT
|
$1.33
30.39%
27.14%
39K
|
Technology Services
VRT
4
|
$79.17
4.08%
19.36%
6.6M
|
Electronic Technology
FOA
4
|
$0.5144
-8.16%
15.43%
20
|
Finance and Insurance
EAST
|
$1.0835
16.17%
15.21%
100
|
Commercial Services
BOF
|
$1.17
6.36%
14.73%
15K
|
TSLA
|
News
|
$144.68
1.85%
9.01%
93M
|
Consumer Durables
BNED
|
$0.2064
2.64%
8.96%
1.4M
|
Retail Trade
HLTH
|
$0.15
6.38%
7.84%
21K
|
LRN
4
|
$58.2
0.17%
7.56%
950K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.